Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml

Hyoung Woo Kim, Young Hwii Ko, Seok Ho Kang, Jeong Gu Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: This study was conducted to identify the predictive factors for prostate cancer in patients with prostate-specific antigen (PSA) levels equal to or less than 4 ng/ml. Materials and Methods: A retrospective study of medical records was conducted on 292 patients with initial serum PSA ≤4 ng/ml among 2,305 patients who underwent prostate biopsy from January 2003 to December 2008. Prostate biopsy was performed on patients with PSA ≤4 ng/ml in the case of abnormal findings in the digital rectal examination (DRE) or transrectal ultrasonography (TRUS) or in those with a PSA level higher than the age-adjusted PSA levels. The patients were divided into the group diagnosed with prostate cancer and the non-prostate-cancer group. Subsequently, the variables of the two groups were compared. Results: The patients' mean age was significantly higher in the prostate cancer group (n=28) than in the non-prostate-cancer group (n=264; p=0.033). In addition, for the patients with a PSA range of 2.0-2.9 ng/ml, their age (p=0.049) and PSA density (PSAD; p=0.042) were significantly higher and the prostate volume (p=0.028) was significantly smaller in the prostate cancer group than in the non-prostate-cancer group. Conclusions: Of the patients with PSA ≤4 ng/ml, the age of the patients who showed abnormal findings in the DRE or TRUS or who had a PSA level higher than the age-adjusted PSA level was a significant predictive factor for prostate cancer. In particular, for the PSA range of 2.0-2.9 ng/ml, a thorough screening test for prostate cancer was required if the patients had conditions such as higher age, smaller prostate, and higher PSAD.

Original languageEnglish
Pages (from-to)166-171
Number of pages6
JournalKorean Journal of Urology
Volume52
Issue number3
DOIs
Publication statusPublished - 2011 Mar 1

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Biopsy
Prostate
Digital Rectal Examination
Ultrasonography
Neoplasms
Medical Records
Retrospective Studies

Keywords

  • Prostate-specific antigen
  • Prostatic neoplasms

ASJC Scopus subject areas

  • Urology

Cite this

Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml. / Kim, Hyoung Woo; Ko, Young Hwii; Kang, Seok Ho; Lee, Jeong Gu.

In: Korean Journal of Urology, Vol. 52, No. 3, 01.03.2011, p. 166-171.

Research output: Contribution to journalArticle

@article{97e8647bc0f54a2ba094ae41f6482a66,
title = "Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml",
abstract = "Purpose: This study was conducted to identify the predictive factors for prostate cancer in patients with prostate-specific antigen (PSA) levels equal to or less than 4 ng/ml. Materials and Methods: A retrospective study of medical records was conducted on 292 patients with initial serum PSA ≤4 ng/ml among 2,305 patients who underwent prostate biopsy from January 2003 to December 2008. Prostate biopsy was performed on patients with PSA ≤4 ng/ml in the case of abnormal findings in the digital rectal examination (DRE) or transrectal ultrasonography (TRUS) or in those with a PSA level higher than the age-adjusted PSA levels. The patients were divided into the group diagnosed with prostate cancer and the non-prostate-cancer group. Subsequently, the variables of the two groups were compared. Results: The patients' mean age was significantly higher in the prostate cancer group (n=28) than in the non-prostate-cancer group (n=264; p=0.033). In addition, for the patients with a PSA range of 2.0-2.9 ng/ml, their age (p=0.049) and PSA density (PSAD; p=0.042) were significantly higher and the prostate volume (p=0.028) was significantly smaller in the prostate cancer group than in the non-prostate-cancer group. Conclusions: Of the patients with PSA ≤4 ng/ml, the age of the patients who showed abnormal findings in the DRE or TRUS or who had a PSA level higher than the age-adjusted PSA level was a significant predictive factor for prostate cancer. In particular, for the PSA range of 2.0-2.9 ng/ml, a thorough screening test for prostate cancer was required if the patients had conditions such as higher age, smaller prostate, and higher PSAD.",
keywords = "Prostate-specific antigen, Prostatic neoplasms",
author = "Kim, {Hyoung Woo} and Ko, {Young Hwii} and Kang, {Seok Ho} and Lee, {Jeong Gu}",
year = "2011",
month = "3",
day = "1",
doi = "10.4111/kju.2011.52.3.166",
language = "English",
volume = "52",
pages = "166--171",
journal = "Korean Journal of Urology",
issn = "2005-6737",
publisher = "Korean Urological Association",
number = "3",

}

TY - JOUR

T1 - Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml

AU - Kim, Hyoung Woo

AU - Ko, Young Hwii

AU - Kang, Seok Ho

AU - Lee, Jeong Gu

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Purpose: This study was conducted to identify the predictive factors for prostate cancer in patients with prostate-specific antigen (PSA) levels equal to or less than 4 ng/ml. Materials and Methods: A retrospective study of medical records was conducted on 292 patients with initial serum PSA ≤4 ng/ml among 2,305 patients who underwent prostate biopsy from January 2003 to December 2008. Prostate biopsy was performed on patients with PSA ≤4 ng/ml in the case of abnormal findings in the digital rectal examination (DRE) or transrectal ultrasonography (TRUS) or in those with a PSA level higher than the age-adjusted PSA levels. The patients were divided into the group diagnosed with prostate cancer and the non-prostate-cancer group. Subsequently, the variables of the two groups were compared. Results: The patients' mean age was significantly higher in the prostate cancer group (n=28) than in the non-prostate-cancer group (n=264; p=0.033). In addition, for the patients with a PSA range of 2.0-2.9 ng/ml, their age (p=0.049) and PSA density (PSAD; p=0.042) were significantly higher and the prostate volume (p=0.028) was significantly smaller in the prostate cancer group than in the non-prostate-cancer group. Conclusions: Of the patients with PSA ≤4 ng/ml, the age of the patients who showed abnormal findings in the DRE or TRUS or who had a PSA level higher than the age-adjusted PSA level was a significant predictive factor for prostate cancer. In particular, for the PSA range of 2.0-2.9 ng/ml, a thorough screening test for prostate cancer was required if the patients had conditions such as higher age, smaller prostate, and higher PSAD.

AB - Purpose: This study was conducted to identify the predictive factors for prostate cancer in patients with prostate-specific antigen (PSA) levels equal to or less than 4 ng/ml. Materials and Methods: A retrospective study of medical records was conducted on 292 patients with initial serum PSA ≤4 ng/ml among 2,305 patients who underwent prostate biopsy from January 2003 to December 2008. Prostate biopsy was performed on patients with PSA ≤4 ng/ml in the case of abnormal findings in the digital rectal examination (DRE) or transrectal ultrasonography (TRUS) or in those with a PSA level higher than the age-adjusted PSA levels. The patients were divided into the group diagnosed with prostate cancer and the non-prostate-cancer group. Subsequently, the variables of the two groups were compared. Results: The patients' mean age was significantly higher in the prostate cancer group (n=28) than in the non-prostate-cancer group (n=264; p=0.033). In addition, for the patients with a PSA range of 2.0-2.9 ng/ml, their age (p=0.049) and PSA density (PSAD; p=0.042) were significantly higher and the prostate volume (p=0.028) was significantly smaller in the prostate cancer group than in the non-prostate-cancer group. Conclusions: Of the patients with PSA ≤4 ng/ml, the age of the patients who showed abnormal findings in the DRE or TRUS or who had a PSA level higher than the age-adjusted PSA level was a significant predictive factor for prostate cancer. In particular, for the PSA range of 2.0-2.9 ng/ml, a thorough screening test for prostate cancer was required if the patients had conditions such as higher age, smaller prostate, and higher PSAD.

KW - Prostate-specific antigen

KW - Prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=79953199082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953199082&partnerID=8YFLogxK

U2 - 10.4111/kju.2011.52.3.166

DO - 10.4111/kju.2011.52.3.166

M3 - Article

VL - 52

SP - 166

EP - 171

JO - Korean Journal of Urology

JF - Korean Journal of Urology

SN - 2005-6737

IS - 3

ER -